View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by Catalent

Case Study: Assessing Potential for Oral Delivery Using Parallel Screening

Free White Paper

Case Study: Assessing Potential for Oral Delivery Using Parallel Screening

By Catalent

Case Study: Assessing Potential for Oral Delivery Using Parallel Screening

By Catalent
Enter your details to receive the free paper:

Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.

This well-known peptide is currently delivered via injection to treat osteoporosis in postmenopausal women. An oral dose is not available due to its poor oral bioavailability.

While Salmon Calcitonin is water soluble, it has poor permeability through tight junctions and limited transcellular pathways doe to its molecular size, geometry, and flexibility.

Catalent’s OptiForm Solution Suite Bio with OptiGel Bio and Zydis Bio technologies were used to overcome duodenal and sublingual barriers with simple candidate formulations.

To find out more about this case study, download this free whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology